Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEEF late effects follow-up cohort after pediatric HSCT and cell therapy
NL-OMON20380Recruiting
- Start
- Dec 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic hematopoietic stem cell transplantation in Immunogenetic disorder, hemoglobinopathies and bone marrow failure, sponsored by None. Primary endpoints: Late effects after pediatric HSCT, Determinants of morbidity, mortality, and treatment outcome and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
allogeneic hematopoietic stem cell transplantation
03
Conditions
Immunogenetic disorderhemoglobinopathiesbone marrow failure
Beyond the preview
Go deeper on NL-OMON20380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20380.